Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Business
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
March 1st, 2008
Altor BioScience Corporation (Altor) announced it has entered into an agreement with Genentech, Inc. for exclusive, worldwide rights to develop and commercialize a class of antibody-based Tissue Factor antagonists. Altor plans on initiating a multi-center, Phase II clinical study later this year, using the lead therapeutic antibody known as ALT-836 for the treatment of Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI). Financial terms of the licensing transaction were not disclosed. Altor also announced that it has been awarded a Phase II Small Business Innovation Research grant from the National Institutes of Health (NIH) of approximately $2.1...
Source: Law & Health Weekly (2008-03-01)
|
